Trial · NCT06068803
Do Ketone Drinks Improve Immune, Metabolic and Cognitive Health in Older Adults
NCT06068803, Not applicable, Completed, University of Bath
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Do Ketone Drinks Improve Immune, Metabolic and Cognitive Health in Older Adults. Trials, record NCT06068803. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06068803
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Do Ketone Drinks Improve Immune, Metabolic and Cognitive Health in Older Adults
- NCT number
- NCT06068803
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 32 participants, actual
- Lead sponsor
- University of Bath
- Conditions
- Aging
- Interventions
- Ketone drink, Placebo
- First posted
- 2023-10-05
- Last updated
- 2026-07-21
Source ClinicalTrials.gov
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in 24hr average glucose area under the curve (AUC) | 1 day during baseline period and 1 day during the intervention period | Glucose control will be measured using a continuous glucose monitoring device worn throughout the baseline period and weeks 3 and 4 of the intervention period. Change in 24h average glucose AUC will be assessed on 'matched meal and activity days' i.e. days during intervention and baseline that are matched for food intake and physical activity. |
| Secondary | Change in glycemic variability | 1 day during baseline period and 1 day during the intervention period | Glucose control will be measured using continuous glucose monitoring device worn throughout the baseline period and weeks 3 and 4 of the intervention period. Change in glycemic variability will be assessed on 'matched meal and activity days' i.e. days during intervention and baseline that are matched for food intake and physical activity. |
| Secondary | Change in serum fructosamine | Pre (day 0) and post (day 29) | Measured in fasting blood sample by automated analyser (Daytona Rx) |
| Secondary | Change in fasting plasma glucose | Pre (day 0) and post (day 29) | Measured in fasting blood sample by automated analyser (Daytona Rx) |
| Secondary | Change in fasting lipid profile concentrations | Pre (day 0) and post (day 29) | Measured in fasting blood sample by automated analyser (Daytona Rx) |
| Secondary | Change in fasting plasma free fatty acids (FFA) | Pre (day 0) and post (day 29) | Measured in fasting blood sample by automated analyser (Daytona Rx) |
| Secondary | Change in fasting plasma insulin | Pre (day 0) and post (day 29) | Measured in fasting blood sample using a high-sensitivity human insulin enzyme-like immunosorbent assay (ELISA) |
| Secondary | Change in Insulin Sensitivity Index | Pre (day 0) and post (day 29) | Calculated from fasting plasma insulin and fasting plasma glucose |
| Secondary | Change in Adipose tissue Insulin Resistance index (Adipo-IR) | Pre (day 0) and post (day 29) | Calculated from fasting plasma insulin and fasting plasma FFA |
| Secondary | Change in body mass | Pre (day 0) and post (day 29) | Measured using a digital body weight scales |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06068803
GET https://conductscience.org/api/trials/v1/NCT06068803/registered?page=2